NASDAQ:DRRX DURECT (DRRX) Stock Price, News & Analysis $1.67 +0.02 (+1.21%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.64▼$1.6950-Day Range$1.04▼$1.7852-Week Range$0.47▼$3.60Volume33,089 shsAverage Volume93,693 shsMarket Capitalization$51.84 millionP/E RatioN/ADividend YieldN/APrice Target$27.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get DURECT alerts: Email Address DURECT MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside1,546.7% Upside$27.50 Price TargetShort InterestBearish4.18% of Float Sold ShortDividend StrengthN/ASustainability-1.19Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($1.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.25 out of 5 starsMedical Sector328th out of 936 stocksPharmaceutical Preparations Industry152nd out of 436 stocks 3.3 Analyst's Opinion Consensus RatingDURECT has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageDURECT has only been the subject of 1 research reports in the past 90 days.Read more about DURECT's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.18% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 7.7.Change versus previous monthShort interest in DURECT has recently increased by 3.39%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for DURECT is -1.19. Previous Next 2.2 News and Social Media Coverage News SentimentDURECT has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for DURECT this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for DRRX on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of DURECT is held by insiders.Percentage Held by InstitutionsOnly 28.03% of the stock of DURECT is held by institutions.Read more about DURECT's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to decrease in the coming year, from ($0.85) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -1.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 3.34. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about DURECT's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About DURECT Stock (NASDAQ:DRRX)DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Read More DRRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRRX Stock News HeadlinesJuly 20, 2024 | finance.yahoo.comDurect Corp (DC8A.SG)May 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)July 27, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 21, 2024 | msn.comDURECT gets FDA breakthrough therapy status for larsucosterolMay 21, 2024 | prnewswire.comDURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated HepatitisMay 14, 2024 | msn.comDURECT Corporation (NASDAQ:DRRX) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comDurect Corp (DRRX) Q1 2024 Earnings Call Transcript Highlights: Navigating Financial Challenges ...May 13, 2024 | prnewswire.comDURECT Corporation Reports First Quarter 2024 Financial Results and Business UpdateJuly 27, 2024 | WealthPress (Ad)New trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.May 12, 2024 | msn.comDURECT Q1 2024 Earnings PreviewMay 7, 2024 | prnewswire.comDURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business UpdateApril 30, 2024 | prnewswire.comDURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated HepatitisApril 1, 2024 | finance.yahoo.comDURECT Corporation (NASDAQ:DRRX) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | benzinga.comDurect: Q4 Earnings InsightsMarch 27, 2024 | markets.businessinsider.comDURECT Corp. Q4 Loss decreases, beats estimatesMarch 27, 2024 | finance.yahoo.comDURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 27, 2024 | msn.comOptions Volatility and Implied Earnings Moves Today, March 27, 2024March 27, 2024 | msn.comDURECT Q4 2023 Earnings PreviewSee More Headlines Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees80Year FoundedN/APrice Target and Rating Average Stock Price Target$27.50 High Stock Price Target$41.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,546.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-27,620,000.00 Net Margins-279.77% Pretax Margin-279.77% Return on Equity-328.25% Return on Assets-76.36% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio0.96 Sales & Book Value Annual Sales$8.55 million Price / Sales6.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book3.34Miscellaneous Outstanding Shares31,040,000Free Float29,704,000Market Cap$51.84 million OptionableOptionable Beta1.04 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. James E. Brown D.V.M. (Age 67)Co-Founder, CEO, President & Director Comp: $633.46kMr. Timothy M. Papp M.B.A. (Age 48)CFO & Secretary Comp: $427.62kDr. Norman L. Sussman M.D. (Age 71)Chief Medical Officer Comp: $471.71kMs. Judy R. Joice (Age 67)Senior Vice President of Operations & Corporate Quality Assurance Comp: $451.82kDr. WeiQi Lin M.D.Ph.D., Executive VP of Research & Development and Principal ScientistMr. Keith L. Lui M.B.A.Senior Vice President of Business Development, Commercial & Medical AffairsMs. Jian Li M.B.A. (Age 54)Senior VP of Finance, Corporate Controller & Secretary Comp: $297.08kDr. Su Il Yum Ph.D. (Age 85)Executive Officer Comp: $331.74kMore ExecutivesKey CompetitorsSelecta BiosciencesNASDAQ:SELBVentyx BiosciencesNASDAQ:VTYXG1 TherapeuticsNASDAQ:GTHXXBiotechNASDAQ:XBITCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInstitutional OwnershipAccredited Investors Inc.Bought 87,627 shares on 7/20/2024Ownership: 0.282%Gagnon Securities LLCBought 21,425 shares on 5/14/2024Ownership: 1.225%Richmond Brothers Inc.Bought 250,050 shares on 5/10/2024Ownership: 2.476%Tocqueville Asset Management L.P.Bought 25,000 shares on 5/10/2024Ownership: 0.826%View All Institutional Transactions DRRX Stock Analysis - Frequently Asked Questions How have DRRX shares performed this year? DURECT's stock was trading at $0.59 on January 1st, 2024. Since then, DRRX stock has increased by 183.1% and is now trading at $1.67. View the best growth stocks for 2024 here. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings results on Monday, May, 13th. The specialty pharmaceutical company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by $0.04. The specialty pharmaceutical company earned $1.83 million during the quarter, compared to analyst estimates of $2.73 million. DURECT had a negative net margin of 279.77% and a negative trailing twelve-month return on equity of 328.25%. When did DURECT's stock split? DURECT's stock reverse split before market open on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Who are DURECT's major shareholders? DURECT's top institutional investors include Accredited Investors Inc. (0.28%). Insiders that own company stock include Judith J Robertson, Gail J Maderis, Gail M Farfel, Mohammad Azab and Simon X Benito. View institutional ownership trends. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some other companies that DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA) and Amarin (AMRN). This page (NASDAQ:DRRX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal war...Behind the Markets | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share DURECT With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
